Ashley Ghiaseddin

University of Florida — United States

Medicine · Health Sciences

11h-index593citations84works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(36), Brain Metastases and Treatment(16), Cancer Immunotherapy and Biomarkers(12), Immunotherapy and Immune Responses(12), CAR-T cell therapy research(12)

Publications84 total

Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial
Nature Communications·2026Open Access
Multiplexed cellular and tissue imaging via plasmonic heating activated signal exchange of DNA probes
2026Open Access
490 Laser interstitial thermal therapy plus pembrolizumab extends survival and ignites anti-tumor immunity in recurrent high-grade astrocytoma: results from a phase 1/randomized phase 2b trial
Regular and Young Investigator Award Abstracts·2025Open Access
CTIM-11. LASER INTERSTITIAL THERMAL THERAPY PLUS PEMBROLIZUMAB PROLONGS SURVIVAL AND ELICITS ROBUST ANTI-TUMOR IMMUNITY IN RECURRENT, REFRACTORY HIGH-GRADE ASTROCYTOMA: A PHASE 1/RANDOMIZED PHASE 2B TRIAL
Neuro-Oncology·2025Open Access
CTIM-34. PARAPROGRESSION DEFINES A DAMAGE RESPONSE FROM SYSTEMIC MRNA IMMUNOTHERAPY IN MALIGNANT GLIOMA
Neuro-Oncology·2025Open Access
Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors
Journal for ImmunoTherapy of Cancer·2025Open Access
EPID-20. The effect of medical comorbidities on survival in GBM: a database study using computed phenotype algorithm for rapid, reliable patient identification
Neuro-Oncology·2025Open Access
QLTI-25. Developing a computable phenotype for primary central nervous system lymphoma
Neuro-Oncology·2025
Systemic mRNA aggregates elicit immunologic reprogramming that unlocks anti-cancer immunity
Human Vaccines & Immunotherapeutics·2025Open Access
Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response
Journal of Clinical Investigation·2025· 2 citedOpen Access
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study
Med·2025· 10 citedOpen Access
A Rare Presentation of Adult Primary Leptomeningeal Medulloblastoma: Case Report
Case Reports in Pathology·2025· 1 citedOpen Access
Opiate Use Patterns Following Surgery for High Grade Glioma
World Neurosurgery·2024Open Access
How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?
Neuro-Oncology Practice·2024· 2 citedOpen Access
Safety and Efficacy of Ketorolac After Craniotomy for Tumor Resection
World Neurosurgery·2024· 2 citedOpen Access
QLTI-16. QUALITY IMPROVEMENT PROJECT (QIPR) FOR IMPLEMENTATION OF PSYCHOSOCIAL ASSESSMENTS FOR ONCOLOGY CLINICAL CARE
Neuro-Oncology·2024Open Access
EXTH-58. BLOCKING IMMUNE CHECKPOINT— LAIR1: DISRUPTING THE LAIR1—FXIII-A—COLLAGEN IMMUNOSUPPRESSIVE CIRCUIT FOR ENHANCED ANTITUMOR THERAPEUTICS
Neuro-Oncology·2024Open Access
591 In-situ vaccination by tumor treating fields and anti-PD-1 immunotherapy in patients with large residual GBM results in robust T cell selection and expansion, high response rate, and extended survival
Regular and Young Investigator Award Abstracts·2024Open Access
CTIM-21. FIRST-IN-HUMAN PHASE I CLINICAL TRIAL USING 8R-70CAR T CELLS FOR NEWLY DIAGNOSED ADULT GLIOBLASTOMA
Neuro-Oncology·2024· 1 citedOpen Access
IMMU-31. DAMAGE RESPONSE FROM SYSTEMIC RNA VACCINATION RESTORES HUMORAL IMMUNITY IN GLIOBLASTOMA
Neuro-Oncology·2024· 1 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Maryam Rahman(26), Kaitlyn Melnick(17), David D. Tran(16), Duane A. Mitchell(14), Paul Castillo(8), Rachel Moor(8), John A. Ligon(8), Jesse Kresak(8), Elias Sayour(8), Katherine B. Peters(7), Dongjiang Chen(7), Anna DeVries(6), Christina A. Von Roemeling(6), Frances Weidert(6), Marcia Hodik(6), Tara Massini(6), Natalie L. Silver(6), David Shin(6), Jianping Huang(6), Sadeem Qdaisat(5)